| 摘要 |
A method of inhibiting, in a biological sample the binding of a CD22 beta -bearing B cell to a second cell bearing a CD22 beta -specific ligand, by contacting the sample with a substance which binds to said CD22 beta -specific ligand to competitively inhibit the binding of the B cell to the second cell. This second cell may, for example, be a T cell or B cell. In addition, the invention features a method of competitively inhibiting the binding of B cells to T cells in a human patient, thereby preventing activation of both T and B cells, by administering an inhibiting amount of a composition including a soluble protein comprising a portion of CD22 beta capable of binding to a CD22 beta -specific ligand on a T cell, and a pharmaceutically acceptable carrier. |
